naphthalimides has been researched along with Leukemia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I | 1 |
Benvenuto, JA; Beran, M; Estey, E; Felder, TB; Keating, M; O'Brien, S | 1 |
1 trial(s) available for naphthalimides and Leukemia
Article | Year |
---|---|
Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adenine; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imides; Isoquinolines; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1991 |
1 other study(ies) available for naphthalimides and Leukemia
Article | Year |
---|---|
Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.
Topics: 1-Naphthylamine; Adenosine Triphosphate; Alkylating Agents; Apoptosis; Benzamides; Cell Death; Cell Line, Tumor; Cell Size; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Melphalan; Methylnitronitrosoguanidine; NAD; Naphthalimides; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones | 2003 |